Clinical Trials on Allogeneic Bone Marrow Transplantation in Belgium

Total 162 results

Universitair Ziekenhuis Brussel

Completed

Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Mesenchymal Stem Cells

Allogeneic Stem Cell Transplantation

Belgium
Universitaire Ziekenhuizen KU Leuven

Unknown

Pharmacokinetics of Posaconazole in Allogeneic Transplant Patients With Mucositis

Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

Belgium
Millennium Pharmaceuticals, Inc.

Terminated

A Dose-Finding Study of Vedolizumab for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Participants Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)

Allogeneic Hematopoietic Stem Cell Transplantation

United States, Belgium, Sweden, France, Norway
Radboud University Medical Center
Universitaire Ziekenhuizen KU Leuven

Completed

Pharmacokinetics of Posaconazole (Noxafil®) as Prophylaxis for Invasive Fungal Infections (PIRAÑA)

Acute Graft Versus Host Disease | Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome

Belgium, Netherlands
University Hospital, Ghent

Completed

Biological Imaging Guided Antalgic Radiotherapy of Bone Metastases (Phase II Trial)

Bone Metastases

Belgium
Radboud University Medical Center

Completed

Pharmacokinetics of Micafungin Given Twice Weekly Intravenously Compared to Micafungin Given Daily to Patients at Risk for Developing an Invasive Fungal Disease (MATADOR)

Allogeneic Stem Cell Transplant | Acute Myeloid Leucaemia | Myelo Dysplastic Syndrome | Acute Graft Versus Host Disease Grade II-IV

Netherlands, Belgium
University Hospital, Ghent

Unknown

Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases

Bone Metastases

Belgium
Tools4Patient

Completed

A Study to Collect Data About Analgesia in Patients With Bone Metastasis

Bone Metastasis

Belgium, France
Novartis Pharmaceuticals

Terminated

A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy. (EXPHAR)

Myelodysplastic Syndrome

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland
CTI BioPharma; Dutch Cancer Society

Active, not recruiting

Myelofibrosis Treated With Pacritinib Before aSCT. (HOVON134MF) (HOVON134MF)

Myelofibrosis

Netherlands, Belgium
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)

Completed

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Polycythemia Vera

Spain, Belgium, Austria, Italy, Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine
Novartis Pharmaceuticals

Completed

Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. (RESPONSE-2)

Polycythemia Vera

Hungary, Italy, Belgium, Germany, Spain, Korea, Republic of, Israel, Canada, Turkey, France, Australia, India
Novartis Pharmaceuticals

Completed

Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Were Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Was Available.

Polycythemia Vera

Germany, Belgium, France, Austria, Canada, Thailand, Norway, Bulgaria, Portugal, Chile, Mexico, Sweden
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium
Ariad Pharmaceuticals

Terminated

A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia (OPTIC-2L)

Chronic Phase Chronic Myeloid Leukemia

Belgium
Novartis Pharmaceuticals

Completed

Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial

Myelofibrosis

France, United Kingdom, Belgium, Germany, Netherlands, Italy, Austria, Spain, Sweden
Incyte Corporation

Completed

Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study

Polycythemia Vera

United States, Belgium, Germany, Spain, Italy, United Kingdom, Ireland
Incyte Corporation

Completed

To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy (LIMBER-213)

Polycythemia Vera | Myelofibrosis | Thrombocythemia

Spain, United States, Germany, Austria, Belgium, Italy, Poland
Incyte Corporation
Novartis Pharmaceuticals

Completed

Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)

Polycythemia Vera

United States, Canada, France, Italy, United Kingdom, China, Belgium, Germany, Spain, Turkey, Japan, Australia, Korea, Republic of, Netherlands, Russian Federation, Argentina, Thailand, Hungary
Universitaire Ziekenhuizen KU Leuven

Completed

A Trial of Zoledronic Acid in Patients With Myelofibrosis With Myeloid Metaplasia (MMM)

Myelofibrosis | Myeloid Metaplasia

Belgium, Australia, France, Germany, Israel, Spain
Protagonist Therapeutics, Inc.

Recruiting

A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera (VERIFY)

Polycythemia Vera

United States, Hong Kong, Israel, Canada, Spain, Australia, Austria, Germany, United Kingdom, Hungary, Netherlands, Czechia, Portugal, Italy, Poland, France, Belgium, Chile, Turkey, Mexico
University Hospital Freiburg

Completed

Assessing Immune Function in Young Patients With Cytopenia That Did Not Respond to Treatment

Myelodysplastic Syndromes | Fanconi Anemia | Dyskeratosis Congenita | Pearson Marrow-pancreas Syndrome | Shwachman-diamond Syndrome

Spain, Germany, Switzerland, Austria, Netherlands, Italy, Czech Republic, Belgium, Denmark, Ireland
European Society for Blood and Marrow Transplantation
Novartis

Completed

Non Interventional Study on Iron Toxicity After First Allo-transplant in MDS/CMML

MDS | CMML

Germany, Belgium, Czechia
Novartis Pharmaceuticals

Completed

A Phase Ib/II Dose-finding Study to Assess the Safety and Efficacy of LDE225 + INC424 in Patients With MF

Bone Marrow Diseases | Hematologic Diseases | Blood Coagulation Disorders | Hemorrhagic Disorders | Primary Myelofibrosis | Myeloproliferative Disorders | Polycythemia Vera | Thrombocytosis | Essential Thrombocythemia | Blood Platelet Disorders

United Kingdom, Belgium, Canada, France, Australia, Netherlands, Spain, Denmark, Ireland, Italy, Germany
European Organisation for Research and Treatment...

Unknown

Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes | Anemia

Belgium, Switzerland, Czech Republic, Portugal, Austria, Netherlands, Slovakia
European Working Group of MDS in Childhood

Unknown

Studying Blood Samples in Young Patients With Cytopenia After a Donor Stem Cell Transplant

Myelodysplastic Syndromes | Leukemia

Germany, Austria, Switzerland, Czech Republic, Netherlands, Denmark, Belgium, Italy, Poland
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Ruxolitinib in the Treatment of Anemic Myelofibrosis Patients. (REALISE)

Primary Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis | Post-Polycythemia Vera-Myelofibrosis

Belgium, Italy, Spain, Bulgaria, Turkey, Greece, Russian Federation, Austria, Canada, Japan, Germany
Novartis Pharmaceuticals

Terminated

Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase

Chronic Myeloid Leukemia in Chronic Phase

Belgium, Germany
Novartis Pharmaceuticals

Completed

A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS Participants (STIMULUS-MDS3)

Myelodysplastic Syndrome (MDS)

France, Spain, Belgium, Italy, Greece, Hungary, Germany
Celgene

Recruiting

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions (INDEPENDENCE)

Primary Myelofibrosis | Myeloproliferative Disorders | Anemia | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis

France, Belgium, Spain, Australia, Canada, United States, Korea, Republic of, Romania, Japan, Israel, Italy, Austria, China, Czechia, Germany, Greece, Ireland, Poland, United Kingdom, Hong Kong, Hungary, Lebanon, Argentina, Chile, Colombia and more
Commissie Voor Klinisch Toegepast Onderzoek

Unknown

Imatinib Mesylate and Cytarabine in Treating Patients With Newly Diagnosed Chronic Myeloid Leukemia

Leukemia

Netherlands, Belgium
European Organisation for Research and Treatment...

Completed

Infliximab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Belgium, Netherlands, Czech Republic, Italy, Germany
Celyad Oncology SA

Recruiting

Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 (CYCLE-1)

Acute Myeloid Leukemia | Myelodysplastic Syndrome

Belgium, United States
Geron Corporation

Completed

Study to Evaluate Activity of 2 Dose Levels of Imetelstat in Participants With Intermediate-2 or High-Risk Myelofibrosis (MF) Previously Treated With Janus Kinase (JAK) Inhibitor

Myelofibrosis

United States, France, Italy, United Kingdom, Belgium, Germany, Taiwan, Spain, Israel, Korea, Republic of, Canada
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia (AML-14A)

Myelodysplastic Syndromes | Leukemia

Belgium, Croatia, France, Italy, Netherlands
AbbVie

Active, not recruiting

A Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm

Myeloproliferative Neoplasm

United States, Belgium, Bulgaria, Croatia, France, Germany, Italy, Japan, Serbia, Spain, Sweden, Taiwan, Turkey, United Kingdom
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
European Organisation for Research and Treatment...

Completed

Idarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

Belgium, Switzerland, Netherlands, Germany
Incyte Corporation

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)

MPN (Myeloproliferative Neoplasms)

United States, France, United Kingdom, Spain, Canada, Japan, Germany, Switzerland, Belgium, Austria, Italy
Teva Branded Pharmaceutical Products R&D, Inc.

Terminated

A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)

Chronic Myeloid Leukemia

United States, Belgium, France, Korea, Republic of
European Organisation for Research and Treatment...

Completed

Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome

Myelodysplastic Syndromes | Leukemia

France, Belgium, Portugal
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
European Organisation for Research and Treatment...

Withdrawn

Monoclonal Antibody Therapy in Treating Patients With Primary Myelodysplastic Syndrome

Myelodysplastic Syndromes

France, Netherlands, Norway, Belgium, Switzerland, Austria, United Kingdom, Germany, Denmark
Janssen Research & Development, LLC

Terminated

A Study Comparing Siltuximab Plus Best Supportive Care to Placebo Plus Best Supportive Care in Anemic Patients With International Prognostic Scoring System Low- or Intermediate-1-Risk Myelodysplastic Syndrome

Myelodysplastic Syndrome

United States, Belgium, Spain, Australia, Sweden, Netherlands, Russian Federation
Novartis Pharmaceuticals

Completed

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

Myelofibrosis | Sickle Cell Disease | Thalassemia | Diamond Blackfan Anemia

United States, Netherlands, Taiwan, Thailand, Italy, Germany, Spain, Canada, Belgium, Greece, Turkey, United Kingdom
University Hospital, Antwerp

Unknown

Observational Study Towards the Impact of Newly Started Treatment in MDS on QoL (Be-QUALMS)

Myelodysplastic Syndromes

Belgium
Astex Pharmaceuticals, Inc.

Active, not recruiting

Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS

Myelodysplastic Syndromes

Spain, United States, Belgium, Canada, Germany, Italy
Geron Corporation

Recruiting

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

Myelofibrosis

United States, Australia, Italy, India, United Kingdom, Israel, Taiwan, Poland, Malaysia, Argentina, Spain, Turkey, Belgium, Germany, Austria, Brazil, Bulgaria, Colombia, Denmark, France, Georgia, Hungary, Korea, Republic of, Portugal, ... and more
University Hospital, Antwerp

Unknown

Efficacy of Dendritic Cell Therapy for Myeloid Leukemia and Myeloma

Acute Myeloid Leukemia | Multiple Myeloma | Chronic Myeloid Leukemia

Belgium
Sanofi

Completed

Phase II, Open Label, Single Arm Study of SAR302503 In Myelofibrosis Patients Previously Treated With Ruxolitinib (JAKARTA2)

Hematopoietic Neoplasm

United States, Austria, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, United Kingdom

Clinical Trials on Allogeneic Bone Marrow Transplantation in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Saint Lucia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations